# Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

> **NCT03130348** · PHASE2 · WITHDRAWN · sponsor: **Mayo Clinic**

## Conditions studied

- Amyloidosis
- Immunoglobulin Light Chain Deposition

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03130348
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-15
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was dropped at site before participation
- **Last updated:** 2018-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03130348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03130348, "Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03130348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*